EWTX director receives 45,150 stock options at $22.34 strike

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. (EWTX) reported a routine equity compensation grant to a director on a Form 4. On November 19, 2025, the reporting person received stock options to purchase 45,150 shares of common stock at an exercise price of $22.34 per share. These options begin vesting on December 19, 2025, with 1/36th of the shares vesting each month, so full vesting occurs over three years as long as the director continues as a service provider through each vesting date. The options have an expiration date of November 19, 2035, meaning they can be exercised anytime after vesting and before that date, subject to the applicable plan and agreement terms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martin Christopher Nathan

(Last) (First) (Middle)

1715 38TH STREET

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$22.34	11/19/2025		A		45,150		(1)	11/19/2035	Common Stock	45,150	$0.00	45,150	D

Explanation of Responses:

1. 1/36th of the shares subject to the option vest each month beginning on December 19, 2025, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

	/s/ John R. Moore, Attorney-in-Fact for Christopher Nathan Martin	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity award did the Edgewise Therapeutics (EWTX) director report on this Form 4?

The reporting person received stock options for 45,150 shares of Edgewise Therapeutics common stock with an exercise price of $22.34 per share.

When do the new Edgewise Therapeutics (EWTX) director options start vesting and over what period?

The options begin vesting on December 19, 2025, with 1/36th of the shares vesting each month, resulting in full vesting over three years if service continues.

What is the expiration date of the reported Edgewise Therapeutics (EWTX) stock options?

The reported stock options expire on November 19, 2035, after which any unexercised portion can no longer be exercised.

What is the role of the reporting person at Edgewise Therapeutics (EWTX)?

The reporting person is identified as a Director of Edgewise Therapeutics, Inc.

Is this Edgewise Therapeutics (EWTX) Form 4 filed for one or multiple reporting persons?

This Form 4 is indicated as being filed by one reporting person, not jointly with others.

What type of security underlies the reported Edgewise Therapeutics (EWTX) stock options?

The derivative security is a stock option (right to buy), and the underlying security is Edgewise Therapeutics common stock, covering 45,150 shares.